

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3524249

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ALLOZYNE, INC.	06/01/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MEDIMMUNE LIMITED
<b>Street Address:</b>	MILSTEIN BUILDING, GRANTA PARK
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	CB21 6GH
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	61801029
<b>Application Number:</b>	61843959
<b>Application Number:</b>	14775684
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	8147473697
<b>Email:</b>	MPYTEL@GLANCELAW.COM
<b>Correspondent Name:</b>	MELISSA J. PYTEL
<b>Address Line 1:</b>	7200 VAN CAMP ROAD
<b>Address Line 2:</b>	GLANCE LAW GROUP, P.C.
<b>Address Line 4:</b>	GIRARD, PENNSYLVANIA 16417
<b>ATTORNEY DOCKET NUMBER:</b>	304.0042USWO
<b>NAME OF SUBMITTER:</b>	KRISTEN LEMME
<b>SIGNATURE:</b>	/Kristen Lemme/
<b>DATE SIGNED:</b>	09/14/2015
<b>Total Attachments: 3</b>	
source=Alloyne to MedImmune Assignment#page1.tif	
source=Alloyne to MedImmune Assignment#page2.tif	
source=Alloyne to MedImmune Assignment#page3.tif	

**PATENT ASSIGNMENT**

Pursuant to that certain Asset Purchase Agreement (the "PURCHASE AGREEMENT") of May 6<sup>th</sup>, 2014 by and between Allozyne, Inc. a Delaware corporation, having a place of business at 1600 Fairview Avenue East, Suite 300, Seattle, WA 98102, USA and formerly of 1616 Eastlake Avenue East, Suite 202, Seattle, WA 98102, USA ("ASSIGNOR) and MedImmune Limited, having a place of business at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom ("ASSIGNEE"), for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR has sold, assigned, and transferred and does hereby sell, assign and transfer to ASSIGNEE, for itself and its successors, transferees, the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the patents and patent applications set forth in Exhibit A hereto ("PATENT RIGHTS"); and
2. The entire worldwide right, title, and interest in and to: (a) the PATENT RIGHTS, including any right of priority; (b) any divisional, continuation, substitute, renewal, reissue, and other related applications thereto which have been or may be filed in the United States or elsewhere in the world; (c) any patents which may be granted on the applications set forth in (a) and (b) above; and (d) the right to sue in its own name and to recover for past infringement of any or all of any applications or patents issuing therefrom.

ASSIGNOR agrees to do the following, as reasonably requested in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titled and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER of the above-identified PATENT RIGHTS; and (3) generally do all lawful acts that ASSIGNEE reasonably requires for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER of the above mentioned PATENT RIGHTS.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the ASSIGNOR has made or will make hereafter no assignment, grant, mortgage, license, or other agreement affecting the rights, titles and interests herein conveyed.

Duly Authorized Representative of ASSIGNOR




Steven Gillis, Director and Chairman

Date of Signature

JUNE 1, 2015

Duly Authorized Representative of ASSIGNEE



Name: Laurie L'Heu Capacity: V.P., IP

Date of Signature

10 JUN, 2015

**Exhibit A**

Allozyne Ref/ Sagittarius IP Ref	Territory	Title	Filing Date	App. No.	Pub. Number	Patent Number (Issue date)	Owner	Status
410-EP ALL-P1029EP	Europe	Amino Acid Substituted Molecules	02-May-07	07776610.3	EP2018437		Allozyne	Pending
410-EP Div1 ALL-P1029EPD1	Europe	Amino Acid Substituted Molecules	29-Jul-11	11175960.1	EP2395099		Allozyne	Pending
410EP-Div2 ALL-P1029EPD2	Europe	Amino Acid Substituted Molecules	29-Jul-11	11175964.3	EP2444499		Allozyne	Pending
410EP-Div3 ALL-P1029EPD3	Europe	Amino Acid Substituted Molecules	09-Jan-13	13150716.2	EP2581450		Allozyne	Pending
410-AU	Australia	Amino Acid Substituted Molecules	02-May-07	2007248680			Allozyne	Granted
410-AUD1	Australia	Amino Acid Substituted Molecules	02-May-07	2013203486			Allozyne	Pending
410-CA	Canada	Amino Acid Substituted Molecules	02-May-07	2,653,748			Allozyne	Pending
410-JP	Japan	Amino Acid Substituted Molecules	02-May-07	2009-509685			Allozyne	Granted
410-C1-EP	Europe	Amino Acid Substituted Molecules	20-Aug-08	08798301.1	EP2190856		Allozyne	Pending
410-C1-CA	Canada	Amino Acid Substituted Molecules	20-Aug-08	2,707,840			Allozyne	Pending
410-US-C3	US	Amino Acid Substituted Molecules	17-Apr-08	12/105,154		7,829,659 09-Nov-09	Allozyne	Granted
410-US-C8	US	Amino Acid Substituted Molecules	16-Oct-13	14/055,651			Allozyne	Pending

Allozyne Ref/ Sagittarius IP Ref	Territory	Title	Filing Date	App. No.	Pub. Number	Patent Number (Issue date)	Owner	Status
P418-US ALL-P1033USC	US	Novel Antibody Derivatives	08-Mar-13	13/791,312			Allozyne	Pending
418-EP ALL-P1033EP	Europe	Novel Antibody Derivatives	10-Sep-11	11752578.2	EP2640745		Allozyne	Pending
418-CN ALL-P1033CN	China	Novel Antibody Derivatives	10-Sep-11	201180054114.9			Allozyne	Pending
418-JP ALL-P1033JP	Japan	Novel Antibody Derivatives	10-Sep-11	2013-527629			Allozyne	Pending

Allozyne Ref/ Sagittarius IP Ref	Territory	Title	Filing Date	App. No.	Pub. Number	Patent Number (Issue date)	Owner	Status
P424USp ALL-P1530USp	US	Novel Nucleic Acid Molecule	15-Mar-13	61/801,029			Allozyne	Converted into PCT
P426USp ALL-P1530USp2	US	Novel Nucleic Acid Molecule	9-Jul-13	61/843,959			Allozyne	Converted into PCT
P427USp ALL-P1574USp	US	Aminoacid Derivatives	5-Aug-13	61/862,497			Allozyne	Pending
P424PCT ALL-P1530PCT	PCT	Novel Nucleic Acid Molecule	14-Mar-14	PCT/EP2014/055210			Allozyne	Pending

Allozyne Ref/ Sagittarius IP Ref	Territory	Title	Filing Date	App. No.	Pub. Number	Patent Number (Issue date)	Owner	Status
P429-WO ALL-P1457PCT	PCT	Cell Lines	24-Sep-13	PCT/EP2013/069887	WO2014044872		Allozyne	Pending
P430-WO ALL-P1605PCT	PCT	Aminoacid Derivatives	24-Sep-13	PCT/EP2013/069888	WO2014044873		Allozyne	Pending

